Profile: Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

12 Sep 2014
Price Change (% chg)

$-0.28 (-1.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Emergent BioSolutions Inc., incorporated in May 1998, is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. In February 2014, the Company acquired Cangene Corporation.

BioDefense Division

The Company’s BioDefense Division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Its programs in this division include a pipeline of investigational product candidates and one marketed product, BioThrax (Anthrax Vaccine Adsorbed), the only vaccine approved by the United States Food and Drug Administration (FDA), for the prevention of anthrax disease. Operations in this division include biologics manufacturing, regulatory and affairs, marketing and sales in support of BioThrax and a product development infrastructure in support of its investigational product candidates.

The Company’s products include BioThrax, BioThrax PEP, NuThrax, PreviThrax, Anthrivig, Thravixa, MVA-85A, SBI-087, TRU-016 and Zanolimumab. The Company also develops preclinical product candidates, including an influenza vaccine and additional protein therapeutics in its SMIP and SCORPION pipelines. The Company developing NuThrax, a product candidate based on BioThrax combined with CPG 7909. The Company develops a recombinant anthrax vaccine, based on original development work at USAMRIID. The Company also developing Anthrivig, a human anthrax immune globulin (AIG), therapeutic product candidate, which is a polyclonal antibody therapeutic, designed as a treatment for patients who have been exposed to anthrax spores and who present with symptoms of anthrax disease, and Thravixa, a human monoclonal antibody therapeutic product candidate as an intravenous treatment for patients who present with symptoms of inhalational anthrax disease.

BioSciences Division

The Company’s BioSciences Division is directed to commercial opportunities and targets oncology, including B-cell malignancies chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL); as well as T-cell malignancies cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma (PTCL); autoimmune and inflammatory disorders (AIID), including rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), and other infectious diseases, such as tuberculosis, influenza and typhoid. Its programs in this division include clinical and preclinical stage investigational product candidates and development programs for its platform technologies. Operations in this division include product development in support of its investigational product candidates, and manufacturing and related infrastructure initiatives in support of its technology platforms.

The Company’s tuberculosis vaccine, designated as MVA85A, is a strain of MVA into which the Antigen 85A gene has been cloned. MVA85A has been designed to increase the immune response to Antigen 85A and thus increase vaccine protective efficacy in individuals previously vaccinated with BCG. As of December 31, 2011, a total of 15 Phase I and three Phase II clinical trials of MVA85A have been completed or are ongoing in the United Kingdom, South Africa, Senegal and the Gambia. The Company completed clinical trials of Typhella in the United States and Europe. Its SMIP and SCORPION protein therapeutics in preclinical development include ES301 (anti-CD3 SMIP protein), X2 (anti-CD86 x IL-10 SCORPION protein) and T-Scorp molecules targeted for solid organ transplant, inflammatory bowel disease, solid tumors and RA.

The Company competes with Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Novartis, Pfizer, Human Genome Sciences, Elusys Therapeutics and PharmAthene.

Company Address

Emergent BioSolutions Inc

ROCKVILLE   MD   20850
P: +1301.7951800
F: +1301.7951899

Search Stocks